Scroll Top

Applications

Human Diagnostics

The Challenge

The SARS-CoV-2 epidemic has shined a light on a major weakness of our healthcare system: the inability to quickly, accurately, and inexpensively screen large groups of individuals for infectious diseases. Such individuals could be community citizens, travelers at airports, attendees at large events, or even employees and patients at healthcare systems themselves. The traditional central laboratory testing model is laborious, expensive, and time-consuming. Results can take 1-3 days to return to the tested patient, which can render testing useless as nearby individuals will be needlessly exposed in the meantime. Furthermore, central laboratory testing in rural and low-income areas can be impossible due to the cost and requirements for electricity and infrastructure. A rapid and portable device will be required to properly conduct pathogen screening as more and more infectious diseases continue to emerge globally.

99
Central laboratory testing is not effective for controlling outbreaks
99
Results take too long to return to the point-of-testing
99
Mass screening is expensive and laborious
The FastDetect Solution

During the COVID outbreak, we saw the opportunity arise to impact public health not only in the USA, but worldwide. Within just a few years, we developed a flexible, scalable, low-cost screening platform based on cutting-edge technology licensed from Caltech. Our engineers joined ultra-high-tech cooling and heating elements with optical instrumentation to develop a system capable of running full PCR within ~15 minutes. Internal components of the device and consumable tests were sourced with scaled manufacturing in mind, and our manufacturing costs are projected to be lower than any competitive device. Initial laboratory testing at FastDetect headquarters has demonstrated >98% sensitivity and specificity for SARS-CoV-2 detection, with a limit of detection down to 100 viral copies per mL of sample. This makes FastDetect the lowest-cost, highest-accuracy molecular diagnostics platform in the world, and it is ready to be deployed to fill this crucial market gap.

99
FastDetect provides results at the point-of-testing in ~15 minutes
99
The testing procedure is simple and does not require additional equipment
99
Accuracy is on-par with leading laboratory machines

Companion Animal Diagnostics

The Challenge

Cats and dogs are severely underdiagnosed and overprescribed with antibiotics, due to the lack of a pathogen detection system that can deliver results during the patient’s visit. In many cases, it has proven simpler to prescribe a best-guess antibiotic based on symptoms, rather than implementing precision medication techniques. This leads to animals suffering with treatable illnesses longer than necessary, and higher ultimate cost to the pet owner by the time the pet has its pathogen cleared. The companion animal health arena could greatly benefit from a rapid diagnostic platform that offers a diverse platform of pathogen detection assays, which would encourage precision medicine in treating animals.

99
Veterinarians lack a point-of-care diagnostic solution for most common pathogens
99
Antibiotics are overprescribed to animals
99
Precision medicine could be improved for dogs and cats alike
The FastDetect Solution

Through multiple industry partnerships and efficient internal R&D, FastDetect is on the path to developing an extensive portfolio of viral and bacterial detection assays. Each assay is projected to display similar high accuracy and short time-to-result, enabling veterinarians to properly screen animals on-site during their visit and prescribe the appropriate treatment based on test results. FastDetect can thus make a significant positive impact on antibiotic stewardship worldwide.

99
FastDetect has a small footprint, about the size of a shoebox
99
The platform will offer a large portfolio of pathogen detection assays
99
The ~15-minute testing time will allow results to be delivered to pets during the same visit

Livestock Diagnostics

The Challenge

Similar to the global SARS-CoV-2 outbreak, dangerous animal viruses and bacterial infections are continually evolving across the world. African Swine Fever Virus and Foot and Mouth Disease have wreaked havoc on global livestock producers, and both viruses have been recently found near USA borders. Without a coordinated defense against the spread of such viruses, the global food supply is at great risk. Importantly, however, livestock producers are extremely cost-sensitive and demand a low cost-per-test for consistent pathogen screening.

99
Dangerous animal pathogens continue to evolve globally and threaten the livestock industry
99
Unchecked outbreaks can decimate entire herds quickly
99
Ultra-low cost-per-test is crucial for regular pathogen screening
The FastDetect Solution

FastDetect has spent the last 12 months optimizing device and consumable cartridge engineering, to create a platform that can be manufactured at an ultra-low cost. No other molecular diagnostics platform in the world can be produced at the price point of FastDetect, which will translate into a low cost-per-test for customers in the livestock production space. Furthermore, the device can be run on battery power, allowing deployment on farms and in rural areas. The FastDetect sample processing procedure is also compatible with pooling of 5+ samples per test. The platform, therefore, embodies a long-awaited solution to the problem of regular pathogen screening on feedlots, farms, and producer locations.

99
FastDetect is portable and can be run on battery power
99
Ultra-lean manufacturing allows a low cost-per-test
99
Sample pooling will allow livestock producers to quickly and consistently monitor herds